Literature DB >> 11888336

Place of polytherapy in the early treatment of epilepsy.

Charles L P Deckers1.   

Abstract

Polytherapy with antiepileptic drugs is not popular mainly because it is thought to be associated with more adverse effects and to contribute relatively little in terms of efficacy compared with monotherapy. However, there are two reasons to question this assumption: certain combinations are more effective than others and, therefore, generalisations about the poor effectiveness of polytherapy cannot be made; and the total drug load, i.e. the total amount of drug exposure for a certain indication, is usually higher in polytherapy, which may explain the higher toxicity seen during such treatment. In this article, the available literature on the effectiveness of first-line monotherapy, alternative monotherapy and second-line polytherapy is reviewed. There is no conclusive evidence in favour for choosing either alternative monotherapy or polytherapy when first-line monotherapy fails. Therefore, a pragmatic approach is recommended until an evidence-based choice can be made.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888336     DOI: 10.2165/00023210-200216030-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  29 in total

Review 1.  Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects.

Authors:  C L Deckers; Y A Hekster; A Keyser; H Meinardi; W O Renier
Journal:  Epilepsia       Date:  1997-05       Impact factor: 5.864

Review 2.  Is there a mechanistic basis for rational polypharmacy?

Authors:  R L Macdonald
Journal:  Epilepsy Res Suppl       Date:  1996

3.  Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group.

Authors:  M J Brodie; J P Mumford
Journal:  Epilepsy Res       Date:  1999-04       Impact factor: 3.045

4.  The efficacy of carbamazepine combinations in epilepsy.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

Review 5.  Monotherapy and polypharmacy.

Authors:  I E Leppik
Journal:  Neurology       Date:  2000       Impact factor: 9.910

6.  Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group.

Authors:  M J Brodie; A W Yuen
Journal:  Epilepsy Res       Date:  1997-03       Impact factor: 3.045

7.  Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment.

Authors:  M W Lammers; Y A Hekster; A Keyser; H Meinardi; W O Renier; H van Lier
Journal:  Epilepsia       Date:  1995-05       Impact factor: 5.864

8.  Monotherapy or polytherapy for epilepsy?

Authors:  E H Reynolds; S D Shorvon
Journal:  Epilepsia       Date:  1981-02       Impact factor: 5.864

9.  A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.

Authors:  R H Mattson; J A Cramer; J F Collins
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

10.  Reduction of polypharmacy in epileptic patients.

Authors:  P Albright; J Bruni
Journal:  Arch Neurol       Date:  1985-08
View more
  4 in total

Review 1.  Combination therapy in epilepsy: when and what to use.

Authors:  Patrick Kwan; Martin J Brodie
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Pharmacovigilance in Pediatric Patients with Epilepsy Using Antiepileptic Drugs.

Authors:  Dorota Kopciuch; Krzysztof Kus; Jędrzej Fliciński; Barbara Steinborn; Anna Winczewska-Wiktor; Anna Paczkowska; Tomasz Zaprutko; Piotr Ratajczak; Elżbieta Nowakowska
Journal:  Int J Environ Res Public Health       Date:  2022-04-08       Impact factor: 4.614

Review 3.  Selecting Rational Drug Combinations in Epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

4.  Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects.

Authors:  Erik K St Louis
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.